Amanta Healthcare IPO – Company Overview

Company Overview: Incorporated in December 1994, Amanta Healthcare Limited is a pharmaceutical company specializing in sterile liquid products. The company develops, manufactures, and markets a wide range of parenteral products packaged in Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technologies. It is also engaged in the production of medical devices.

Amanta Healthcare’s product range includes:

• Fluid therapy formulations (IV fluids, diluents)

• Ophthalmic solutions and respiratory care products

• Irrigation solutions, first-aid products, and eye lubricants

The company operates through three business units:

1. National Sales

2. International Sales

3. Product Partnering with foreign and Indian pharmaceutical companies

Amanta has built a strong presence in India and global markets. It markets over 45 generic products in India through 320 distributors and stockists, while also exporting branded products to 21 countries, including Africa, Latin America, and the UK. Its products are registered in 19 countries and meet international compliance standards. Objects of the Issue:

1. Capital expenditure for new SteriPort manufacturing line – ₹70 Cr (55.5%)

2. Capital expenditure for new SVP manufacturing line – ₹30.13 Cr (24%)

3. General corporate purposes – ₹25.87 Cr (20.5%)

Strengths:

1. Established Legacy (Since 1994): Over three decades of operations with proven credibility in the pharmaceutical industry.

2. Diverse Product Portfolio: Wide range of sterile liquid formulations and medical devices catering to domestic and global healthcare needs.

3. Advanced Manufacturing Capabilities: Facilities equipped with ABFS and ISBM technologies, enabling production across multiple volume ranges.

4. Strong Quality Certifications: Plants certified with ISO and WHO-GMP, ensuring compliance with international regulatory standards.

5. Extensive Market Reach: Presence across India with 320 distributors and exports to 21 international markets, including product registrations in 19 countries.

6. Experienced Leadership & Skilled Workforce: Backed by a 1,700+ member team of qualified professionals and industry experts.

Risk Factors:

1. Revenue Dependency on Limited Customers: High customer concentration may impact stability and expose the business to dependency risks.

2. Execution Risks in Expansion: Any delays in SteriPort and SVP capacity expansion may hinder future growth.

3. Financial Obligations: Promoter guarantees tied to loans could create operational and financial pressure.

4. Product Liability Concerns: Sterile liquid products inherently carry risks of product liability, which could impact reputation and finances.

Amanta Healthcare IPO: Key Details

• IPO Dates: 1 to 3 Sept 2025

• Price Band: ₹120 – ₹126

• Lot Size: 119 Shares

• Total Issue Size: ₹126 Cr

• Retail Quota: 35%

• GMP: 13% (only for information)

Allotment Link

DISCLAIMER: No financial information whatsoever published anywhere here should be construed as an offer to buy or sell securities, or as advice to do so in any way whatsoever. All matters published here are purely for educational and information purposes only and under no circumstances should be used for making investment decisions. Readers must consult a qualified financial advisor before making any actual investment decisions, based on the information published here. Any reader making decisions based on any information published here does so entirely at their own risk. Investors should bear in mind that any investment in the stock market is subject to unpredictable market-related risks. The author has no plans to invest in this offer and also the author does not recommend investing in any offer published on this website.